Fibrinogen and the risk of thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 1, 2010, Pages 7-17

  De Moerloose, Philippe ^a   Boehlen, Françoise ^a   Neerman Arbez, Marguerite ^a,b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Afibrinogenemia; Dysfibrinogenemia; Fibrinogen; Hyperfibrinogenemia; Hypofibrinogenemia; Polymorphisms; Thrombosis

Indexed keywords

FIBRINOGEN;

AFIBRINOGENEMIA; BLEEDING; FIBRINOGEN BLOOD LEVEL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; HYPERCOAGULABILITY; HYPOFIBRINOGENEMIA; INFLAMMATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FIBRINOGEN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; POLYMORPHISM, GENETIC; RISK; THROMBOEMBOLISM; THROMBOSIS;

EID: 77951055040     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1248720     Document Type: Review

References (73)

1. de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009 35 (4) 356-366
2. Kant J A., Fornace A J. Jr, Saxe D, Simon M I., McBride O W., Crabtree G R. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A 1985 82 (8) 2344-2348
3. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998 279 (18) 1477-1482 (Pubitemid 28228207)
4. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003 89 (4) 601-609 (Pubitemid 36456957)
5. Danesh J, Lewington S, Thompson S G. et al, Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005 294 (14) 1799-1809 (Pubitemid 41434626)
6. Kaptoge S, White I R., Thompson S G. et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: Individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007 166 (8) 867-879 (Pubitemid 47511690)
7. Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost 2007 5 (9) 1795-1800 (Pubitemid 47288932)
8. Welsh P, Woodward M, Rumley A, Lowe G. Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. Br J Haematol 2008 141 (6) 852-861 (Pubitemid 351724867)
9. del Zoppo G J., Levy D E., Wasiewski W W. et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 2009 40 (5) 1687-1691
10. Chuang S Y., Bai C H., Chen W H., Lien L M., Pan W H. Fibrinogen independently predicts the development of ischemic stroke in a Taiwanese population: CVDFACTS study. Stroke 2009 40 (5) 1578-1584
11. Koster T, Rosendaal F R., Reitsma P H., van der Velden P A., Brit E, Vandenbroucke J P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphismsthe Leiden Thrombophilia Study (LETS). Thromb Haemost 1994 71 (6) 719-722
12. Kamphuisen P W., Eikenboom J C., Vos H L. et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999 81 (5) 680-683
13. van Hylckama Vlieg A, Rosendaal F R. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 2003 1 (12) 2677-2678
14. Daskalopoulou S S., Daskalopoulos M E., Liapis C D., Mikhailidis D P. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 2005 12 (4) 443-452
15. Schneider D J., Taatjes D J., Howard D B., Sobel B E. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk. J Am Coll Cardiol 1999 33 (1) 261-266
16. Falls L A., Farrell D H. Resistance of gammaA/gamma fibrin clots to fibrinolysis. J Biol Chem 1997 272 (22) 14251-14256
17. Lepedda A J., Cigliano A, Cherchi G M. et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis 2009 203 (1) 112-118
18. Hicks R C., Golledge J, Mir-Hasseine R, Powell J T. Vasoactive effects of fibrinogen on saphenous vein. Nature 1996 379 (6568) 818-820 (Pubitemid 26067721)
19. Retzinger G S., DeAnglis A P., Patuto S J. Adsorption of fibrinogen to droplets of liquid hydrophobic phases. Functionality of the bound protein and biological implications. Arterioscler Thromb Vasc Biol 1998 18 (12) 1948-1957
20. Rabbani L E., Loscalzo J. Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis 1994 105 (1) 1-7 (Pubitemid 24047742)
21. Hamsten A, Mannila M N., Silveira A. Quest for genes regulating plasma fibrinogen concentration: still a long way to go. Arterioscler Thromb Vasc Biol 2005 25 (6) 1100-1101 (Pubitemid 40776594)
22. Soria J M., Almasy L, Souto J C. et al. A genome search for genetic determinants that influence plasma fibrinogen levels. Arterioscler Thromb Vasc Biol 2005 25 (6) 1287-1292 (Pubitemid 40776623)
23. Yang Q, Tofler G H., Cupples L A. et al. A genome-wide search for genes affecting circulating fibrinogen levels in the Framingham Heart Study. Thromb Res 2003 110 (1) 57-64 (Pubitemid 36859856)
24. Dehghan A, Yang Q, Peters A et al. Association of novel genetic Loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohorts. Circ Cardiovasc Genet. 2009 2 125-133
25. Ridker P M., Chasman D I., Zee R Y. et al, Womens Genome Health Study Working Group. Rationale, design, and methodology of the Womens Genome Health Study: a genome-wide association study of more than 25,000 initially healthy American women. Clin Chem 2008 54 (2) 249-255
26. van der Krabben M D., Rosendaal F R., van der Bom J G., Doggen C J. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost 2008 6 (5) 720-725
27. Carty C L., Cushman M, Jones D et al. Associations between common fibrinogen gene polymorphisms and cardiovascular disease in older adults. The Cardiovascular Health Study. Thromb Haemost 2008 99 (2) 388-395 (Pubitemid 351230971)
28. Reiner A P., Carty C L., Carlson C S. et al. Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Thromb Haemost 2006 4 (6) 1279-1287 (Pubitemid 43756706)
29. Jood K, Danielson J, Ladenvall C, Blomstrand C, Jern C. Fibrinogen gene variation and ischemic stroke. J Thromb Haemost 2008 6 (6) 897-904 (Pubitemid 351689909)
30. Smith G D., Harbord R, Milton J, Ebrahim S, Sterne J A. Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol 2005 25 (10) 2228-2233 (Pubitemid 41416326)
31. Rallidis L S., Gialeraki A, Fountoulaki K et al. G-455A polymorphism of beta-fibrinogen gene and the risk of premature myocardial infarction in Greece. Thromb Res 2009 April 30 (Epub ahead of print)
32. Cheung E Y., Bos M J., Leebeek F W. et al. Variation in fibrinogen FGG and FGA genes and risk of stroke: the Rotterdam Study. Thromb Haemost 2008 100 (2) 308-313
33. van Oijen M, Cheung E Y., Geluk C E. et al. Haplotypes of the fibrinogen gene and cerebral small vessel disease: the Rotterdam scan study. J Neurol Neurosurg Psychiatry 2008 79 (7) 799-803 (Pubitemid 351914727)
34. Carter A M., Catto A J., Grant P J. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999 99 (18) 2423-2426
35. Carter A M., Catto A J., Kohler H P., Arins R A., Stickland M H., Grant P J. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 2000 96 (3) 1177-1179 (Pubitemid 30616891)
36. Standeven K F., Grant P J., Carter A M., Scheiner T, Weisel J W., Arins R AS. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003 107 (18) 2326-2330 (Pubitemid 36578503)
37. Siegerink B, Rosendaal F R., Algra A. Genetic variation in fibrinogen; its relationship to fibrinogen levels and the risk of myocardial infarction and ischemic stroke. J Thromb Haemost 2009 7 (3) 385-390
38. Behague I, Poirier O, Nicaud V et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Tmoins sur lInfarctus du Myocarde. Circulation 1996 93 (3) 440-449 (Pubitemid 26043602)
39. Mosesson M W. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003 89 (1) 9-12
40. Lovely R S., Falls L A., Al-Mondhiry H A. et al. Association of gammaA/gamma fibrinogen levels and coronary artery disease. Thromb Haemost 2002 88 (1) 26-31 (Pubitemid 34752262)
41. Uitte de Willige S U., de Visser M C., Houwing-Duistermaat J J., Rosendaal F R., Vos H L., Bertina R M. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma levels. Blood 2005 106 (13) 4176-4183
42. Rosendaal F R., Reitsma P H. Genetics of venous thrombosis. J Thromb Haemost 2009 7 (suppl 1) 301-304
43. de Willige S U., Pyle M E., Vos H L. et al. Fibrinogen gamma gene 3-end polymorphisms and risk of venous thromboembolism in the African-American and Caucasian population. Thromb Haemost 2009 101 (6) 1078-1084
44. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost 2009 102 (2) 360-370
45. Kurnik D, Lubetsky A. Genetic variants and risk for venous thromboembolic events: summing up the evidence. Thromb Haemost 2009 102 (2) 183-184
46. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995 73 (1) 151-161
47. Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002 126 (11) 1387-1390 (Pubitemid 36237289)
48. McDonagh J. Dysfibrinogenemia and other disorders of fibrinogen structure or function In: Colman R, Hirsh J, Marder V, Clowes A, George J Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia, PA Lippincott Williams & Wilkins 2001 855-892
49. Morris T A., Marsh J J., Chiles P G. et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009 114 (9) 1929-1936
50. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci P M. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999 107 (1) 204-206 (Pubitemid 29500827)
51. Dupuy E, Soria C, Molho P et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001 102 (3) 211-219 (Pubitemid 32441709)
52. Acharya S S., Coughlin A, Dimichele D M., North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004 2 (2) 248-256
53. Bolton-Maggs P H., Perry D J., Chalmers E A. et al. The rare coagulation disordersreview with guidelines for management from the United Kingdom Haemophilia Centre Doctors Organisation. Haemophilia 2004 10 (5) 593-628
54. Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia 2006 12 (4) 345-351
55. De Marco L, Girolami A, Zimmerman T S., Ruggeri Z M. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 1986 77 (4) 1272-1277 (Pubitemid 16047149)
56. Korte W, Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. Clin Investig 1994 72 (5) 396-398
57. de Bosch N B., Mosesson M W., Ruiz-Sez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (antithrombin I). Thromb Haemost 2002 88 (2) 253-258
58. Ni H, Denis C V., Subbarao S et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000 106 (3) 385-392
59. Remijn J A., Wu Y-P, Ijsseldijk M J., Zwaginga J J., Sixma J J., de Groot P G. Absence of fibrinogen in afibrinogenemia results in large but loosely packed thrombi under flow conditions. Thromb Haemost 2001 85 (4) 736-742
60. Di Napoli M, Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients?: why, how, and when. Stroke 2009 40 (5) 1549-1552
61. Hoegee-de Nobel E, Voskuilen M, Brit E, Brommer E J., Nieuwenhuizen W. A monoclonal antibody-based quantitative enzyme immunoassay for the determination of plasma fibrinogen concentrations. Thromb Haemost 1988 60 (3) 415-418
62. Gabay C, Roux-Lombard P, de Moerloose P, Dayer J M., Vischer T, Guerne P A. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993 20 (5) 815-821
63. Peters A, Greven S, Heid I M. et al, AIRGENE Study Group. Fibrinogen genes modify the fibrinogen response to ambient particulate matter. Am J Respir Crit Care Med 2009 179 (6) 484-491
64. Jacquemin B, Antoniades C, Nyberg F et al. Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol 2008 52 (11) 941-952
65. Dargaud Y, Trzeciak M C., Bordet J C., Ninet J, Negrier C. Use of calibrated automated thrombinography+/ thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006 96 (5) 562-567
66. Ingerslev J, Srensen B, Castaman G, Lloyd J V., Varon J D., Savion N. New approaches in the measurement of coagulation. Haemophilia 2008 14 (suppl 3) 104-112
67. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994 25 (9) 1755-1759
68. Sherman D G., Atkinson R P., Chippendale T et al. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000 283 (18) 2395-2403
69. Hennerici M G., Kay R, Bogousslavsky J et al. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet 2006 368 (9550) 1871-1878
70. Levy D E., Trammel J, Wasiewski W W., Ancrod Stroke Program (ASP) Study Team. Ancrod for acute ischemic stroke: a new dosing regimen derived from analysis of prior ancrod stroke studies. J Stroke Cerebrovasc Dis 2009 18 (1) 23-27
71. Lynch A I., Boerwinkle E, Davis B R. et al. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenet Genomics 2009 19 (6) 415-421
72. de Moerloose P, Neerman-Arbez M. Treatment of congenital fibrinogen disorders. Expert Opin Biol Ther 2008 8 (7) 979-992
73. Schuepbach R A., Meili E O., Schneider E, Peter U, Bachli E B. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia. Thromb Haemost 2004 91 (5) 1044-1046